{"id":1795,"date":"2022-11-22T15:28:18","date_gmt":"2022-11-22T15:28:18","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1795"},"modified":"2026-02-23T00:27:22","modified_gmt":"2026-02-23T00:27:22","slug":"uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/","title":{"rendered":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson)"},"content":{"rendered":"

Pathogenic variants in RAD51C, RAD51D, BRIP1<\/em> are established ovarian cancer predisposition genes. PALB2<\/em> is firmly recognised as a breast cancer predisposition gene and more recently associated with ovarian cancer.\u00a0 An association of RAD51C <\/em>and RAD51D<\/em> with breast cancer predisposition was recently confirmed. Whilst improved cancer risks estimates for these genes are available, to date no UK clinical management guidelines for gene carriers have been published. With expansion of genetic testing, a clinical need for such guidelines was recognised. The UK Cancer Genetics Group in collaboration with the CanGene-CanVar project convened a two-day national consensus meeting with relevant experts and stakeholders to reach agreement on consistent clinical management of breast and ovarian cancer risk, particularly with respect to appropriateness and timing of risk-reducing gynaecological surgery, breast surveillance and risk reducing mastectomy. This paper presents a summary of the processes used to reach and agree consensus, as well as the key recommendations from the meeting. (https:\/\/jmg.bmj.com\/content\/early\/2022\/11\/21\/jmg-2022-108898<\/a> )<\/p>\n","protected":false},"excerpt":{"rendered":"

Pathogenic variants in RAD51C, RAD51D, BRIP1 are established ovarian cancer predisposition genes. PALB2 is firmly recognised as a breast cancer predisposition gene and more recently associated with ovarian cancer.\u00a0 An association of RAD51C and RAD51D with breast cancer predisposition was recently confirmed. Whilst improved cancer risks estimates for these genes are available, to date no […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1795","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nUK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Pathogenic variants in RAD51C, RAD51D, BRIP1 are established ovarian cancer predisposition genes. PALB2 is firmly recognised as a breast cancer predisposition gene and more recently associated with ovarian cancer.\u00a0 An association of RAD51C and RAD51D with breast cancer predisposition was recently confirmed. Whilst improved cancer risks estimates for these genes are available, to date no [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-22T15:28:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-23T00:27:22+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/22\\\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/22\\\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson)\",\"datePublished\":\"2022-11-22T15:28:18+00:00\",\"dateModified\":\"2026-02-23T00:27:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/22\\\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\\\/\"},\"wordCount\":196,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/22\\\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/22\\\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/22\\\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\\\/\",\"name\":\"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2022-11-22T15:28:18+00:00\",\"dateModified\":\"2026-02-23T00:27:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/22\\\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/22\\\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/22\\\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/","og_locale":"en_US","og_type":"article","og_title":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson) - JMG Contact blog","og_description":"Pathogenic variants in RAD51C, RAD51D, BRIP1 are established ovarian cancer predisposition genes. PALB2 is firmly recognised as a breast cancer predisposition gene and more recently associated with ovarian cancer.\u00a0 An association of RAD51C and RAD51D with breast cancer predisposition was recently confirmed. Whilst improved cancer risks estimates for these genes are available, to date no [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/","og_site_name":"JMG Contact blog","article_published_time":"2022-11-22T15:28:18+00:00","article_modified_time":"2026-02-23T00:27:22+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson)","datePublished":"2022-11-22T15:28:18+00:00","dateModified":"2026-02-23T00:27:22+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/"},"wordCount":196,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/","url":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/","name":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2022-11-22T15:28:18+00:00","dateModified":"2026-02-23T00:27:22+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/22\/uk-consensus-recommendations-for-clinical-management-of-cancer-risk-for-women-with-germline-pathogenic-variants-in-cancer-predisposition-genes-rad51c-rad51d-brip1-and-palb2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 (Contributed by Dr Helen Hanson)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1795"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1795\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}